Synopsis
With more than 100 clinically approved small molecules, the field of kinase modulation continues to attract significant investment from the drug discovery community and attention from academia. The 11th RCS-BMCS/SCI symposium on kinase inhibitor design will encompass plenary lectures on emerging topics and case studies of ongoing programmes as well as successful past programmes. A range of topics including brain penetrant and inhaled kinase inhibitors, kinase chemical probes, allosteric modulators, targeted kinase protein degradation and kinase inhibition for non-oncology indications will be covered, along with views and perspectives on the future of kinase modulator research.
Important links and downloads
X hashtag 鈥� #Kinase2025
Organising Committee
Helen Aylott, Redx Pharma
John Cumming, Roche
Ray Finlay, AstraZeneca
Pascal Savy, Isomorphic Labs
Asier Unciti-Broceta, University of Edinburgh
With more than 100 clinically approved small molecules, the field of kinase modulation continues to attract significant investment from the drug discovery community and attention from academia. The 11th RCS-BMCS/SCI symposium on kinase inhibitor design will encompass plenary lectures on emerging topics and case studies of ongoing programmes as well as successful past programmes. A range of topics including brain penetrant and inhaled kinase inhibitors, kinase chemical probes, allosteric modulators, targeted kinase protein degradation and kinase inhibition for non-oncology indications will be covered, along with views and perspectives on the future of kinase modulator research.
Important links and downloads
X hashtag 鈥� #Kinase2025
Organising Committee
Helen Aylott, Redx Pharma
John Cumming, Roche
Ray Finlay, AstraZeneca
Pascal Savy, Isomorphic Labs
Asier Unciti-Broceta, University of Edinburgh
